Drug Profile
Research programme: monoclonal antibody biosimilars - NeuClone
Latest Information Update: 22 Mar 2016
Price :
$50
*
At a glance
- Originator NeuClone
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase Unknown Cancer; Inflammation
Most Recent Events
- 22 Mar 2016 Research programme: monoclonal antibody biosimilars - NeuClone is available for licensing as of 22 Mar 2016. http://www.neuclone.com
- 22 Mar 2016 Investigation in Cancer in Australia (Parenteral)
- 22 Mar 2016 Investigation in Inflammation in Australia (Parenteral)